Kamada Ltd, Israel

Plasma protein fractions. Plasma protein fraction 200 g/l.
Plasma protein fraction  human albumin 200 g/l
VIAL Sol. for inf.  1 X50/100 ml  
Dose depends on ptt size, sev. of condit. and on contin. fluid or protein losses. See lit.
Restorat. and maint. of circul. blood vol. where vol. defic. has been demonstr. and use of a colloid is appropr. The choice of albumin rather than artif. colloid will dep. on the clin. situat. of the indiv. ptt, based on official recomm.
C/I: Hypersens.

Monoclonal Antibody, VEGF Inhibitor. Bevacizumab 25 mg / 1 ml.
Concentr. for sol. for IV vials:1 X 4 ml/16ml
Dosage to be adj. indiv. as per med. condit. and combinat. regimen accord. to prescrib. info.
In combin. with fluoropyrimidine-based chemother.  for metast. carcin. of the colon or rectum.- In addit. to platinum - based chemoth. for first - line tmt. of unresectable adv. metast. or recurr. non- small cell lung cancer other than predom. squam. cell histol. –In combin. with interferon alfa-2a for first line of adv. and /or metast. renal cell cancer. In combin. with paclitaxel for first-line tmt. of metast. breast cancer.- As a sgle. agent, for glioblastoma in pts. with progress. dis. following prior ther.- In combin. with carboplatin and paclitaxel, for front-line tmt. of adv.(FIGO stages III B, III C and IV) epithelial ovarian, fallopian tube, or prim. peritoneal cancer at high risk for recurr.- In combin. with carboplatin and gemcitabine, for first recurr. of platinum-sensit. epithelial ovarian, fallopian tube or prim. peritoneal cancer pts. who have not received prior ther. with bevacizumab or other VEGF inhibit. or VEGF receptor-targeted agents.- In combin. with topotecan, or pegylated liposomal doxorubicin for platinum-resistant recurr. epithelial ovarian, fallopian tube, or prim. peritoneal cancer pts. who received no more than 2 prior chemother. regimens and who have not receved prior ther. with bevacizumab or other VEGF inhib. or VEGF recept.–targeted agents –In combin. with paclitaxel and cisplatin or paclitaxel and topotecan for persistent, recurr., or metast. carcin. of the cervix.- In combin. with erlotinib, for first-line tmt. of unresectable adv., metast. or recurr. non-squam. non-small cell lung cancer with Epid. Growth Factor Recept.(EGFR) activat. mutat.
C/I: hypersens, incl. to Chin. Hamster Ovary (CHO) cell prod. or other recomb. human or humanized antibodies. Pregn.

Gonadotropin Releasing Hormone Analogues. Leuprorelin Acetate 22.5, 45 mg.
PRE-FILLED SYR. (1 pwdr. for inj. + 1 solv. cyclic olefin copolymer): 1.
22.5 mg  is admin. as a single SC inject. every 3 mnths. The inject. sol. forms a solid med. product deliv. depot and provides cont. release of leuprorelin acetate over a 3 -month period. 45 mg is admin. as a single SC inject. every 6 mnths. The inject. sol. forms a solid med. product deliv. depot and provides cont. release of leuprorelin acetate over a 6 -month period. See lit.
Tmt. of hormone depend. advanced prostate cancer.
C/I: Use in women. Paed.  pts. Hypersens.  to leuprorelin acetate, to other GnRH agon. In pts. who prev. underwent orchiectomy (as with other GnRH agon., Leuprorelin Acetate does not result in further decr. of serum testoster. in case of surg. castration). As sole tmt. in prostate cancer pts. with spinal cord compres. or evidence of spinal metastases.

LMWH. Enoxaparin 100 mg/ml, Enoxaparin 150 mg/ml.
Pre-filled syr. with sol. for SC inj./IV bolus during hemodialysis.
2/10 X 12,000 IU (120 mg / 0.8 ml )
2/10 X 15,000 IU (150 mg/1 ml )
Dosage to be indiv. adjust. by physic. according to weight and med. condit. of ptt
• Prophylaxis of venous thromboembolic dis. in moder. and high -risk surgical pts, in particular those undergoing orthopaedic or gral surgery incl. cancer surgery. • Prophylaxis of venous thromboembolic dis. in pts with an acute illness (such as acute HF, resp. insuff., sev. infections or rheumatic dis.) and reduced mobility at incr. risk of venous thromboembolism. • Tmt. of deep vein thrombosis(DVT) and pulmonary embolism (PE), excl. PE likely to require thrombolytic ther. or surgery. • Prevention of thrombus formation in extra corporeal circul. during haemodialysis. • Acute coronary syndr: Tmt. of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combin. with oral acetylsalicylic acid. – Tmt. of acute ST-segment elevation myocardial infarction (STEMI) incl. pts to be managed medic. or with subsequent percutaneous coronary intervention (PCI).
C/I: Hypersens. incl to heparin and deriv./ Hist. of immune mediated heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies/ Active clin. signif. bleeding and conditions with a high risk of haemorrhage, incl. recent haemorrhagic stroke, GI ulcer, presence of malign. neoplasm at high risk of bleeding, recent brain, spinal or ophthalmic surgery, known or suspect. oesophageal varices, arteriovenous malform., vasc. aneurysms or major intraspinal or intracerebral vasc. abnormalities/ Spinal or epidural anaesthesia or loco-regional anaesthesia when enoxaparin sodium is used for tmt. in the previous 24 hs.

Corticosteroid, β2 Agonist. Beclometasone Dipropionate 100 mcg, Formoterol Fumarate 6 mcg.
INHALER.(pressurised  sol. for inhal.):1×120 actuat.
Asthma: Maint. therapy for pts. 18 yrs. and above- 1, 2 inhal. ×2/d. max. dly. dose is 4 inhal. Maint. & reliever ther.: Pts. 18 yrs. and above- 1 inhal. ×2/d. max. dly. dose is 8 inhal.COPD: For pts. 18 yrs. and above- 2 inhal. ×2/d. See lit.
Asthma: Regular tmt. of asthma where use of a combin. product (inhaled corticost.&long-acting β2-agonist) is approp. Pts. not adequate. control. with inhal. corticoster. and ‘as needed’ inhal. rapid-act. beta2-agonist. Pts. already adequat. control. on both inhal. corticoster. and long-act. β2-agonist. COPD :Symptom. tmt. of pts. with severe COPD (FEV1 < 50% predicted normal) and a hist. of repeated exacerb., who have signific. sympt. despite regular ther. with long-act. bronchodilators.
C/I: Hypersens.

Corticosteroid/Beta 2-Agonist. Beclometasone Dipropionate 200mcg/metered dose, Formoterol Fumarate 6mcg/metered dose.
INHALER. (Pressurised sol. for inhal).:1×120 actuation.
Adults 18 yrs. and above:
Two inhalations twice dly.
The max. dly. dose is 4 inhalat.
Foster 200/6 should be used as mainten. therapy only. A lower strength (Foster 100/6) is available for mainten. and reliever ther.
Indicated in the regular tmt. of asthma in adult. where use of a comb. product (inhaled corticosteroid and long-act. Β₂-ag.) is appropriate:
Pts. not adequate. control. with inhaled corticosteroids and 'as needed' inhaled rapid-acting Β2-agonist.
Pts. already adequat. controlled on both inhaled corticosteroids and long-act. Β2-ag. C/I: Hypersens.